Subcutaneous immunotherapy for bee venom allergy induces epitope spreading and immunophenotypic changes in allergen-specific memory B cells - 26/09/24
Graphical abstract |
Abstract |
Background |
Allergen immunotherapy (AIT) is the only disease-modifying treatment for allergic disorders. We have recently discovered that allergen-specific memory B cells (Bmem) are phenotypically altered after 4 months of sublingual AIT for ryegrass pollen allergy. Whether these effects are shared with subcutaneous allergen immunotherapy (SCIT) and affect the epitope specificity of Bmem remain unknown.
Objective |
The study aimed to evaluate the phenotype and antigen receptor sequences of Bmem specific to the major bee venom (BV) allergen Api m 1 before and after ultra-rush SCIT for BV allergy.
Methods |
Recombinant Api m 1 protein tetramers were generated to evaluate basophil activation in a cohort of individuals with BV allergy before and after BV SCIT. Comprehensive flow cytometry was performed to evaluate and purify Api m 1–specific Bmem. Immunoglobulin genes from single Api m 1–specific Bmem were sequenced and structurally modeled onto Api m 1.
Results |
SCIT promoted class switching of Api m 1–specific Bmem to IgG2 and IgG4 with increased expression of CD23 and CD29. Furthermore, modeling of Api m 1–specific immunoglobulin from Bmem identified a suite of possible new and diverse allergen epitopes on Api m 1 and highlighted epitopes that may preferentially be bound by immunoglobulin after SCIT.
Conclusions |
AIT induces shifting of epitope specificity and phenotypic changes in allergen-specific Bmem.
Le texte complet de cet article est disponible en PDF.Key words : Immunotherapy, allergen-specific, memory B cells, allergen epitopes
Abbreviations used : AIT, APC, BAT, BCR, Bmem, BV, fMLP, SCIT, SLIT
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?